Pawan Kumar Raut

Pawan Kumar Raut

Auto-generated profile, based on publicly available information

Pawan Kumar Raut

National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
KCKyung-Soo Chun
Kyung-Soo Chun
PRPawan Kumar Raut
Pawan Kumar Raut
DKDo-Hee Kim
Do-Hee Kim
Young-Joon SurhYoung-Joon Surh
Young-Joon Surh


20 November 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
SBSalah Boudjadi
Salah Boudjadi
HKHana Kim
Hana Kim
BCBishwanath Chatterjee
Bishwanath Chatterjee
PRPawan Kumar Raut
Pawan Kumar Raut
TNThanh Hung Nguyen
Thanh Hung Nguyen
FBFrederic G. Barr
Frederic G. Barr
We previously used a myoblast model of fusion-positive rhabdomyosarcoma (FP-RMS) to show that FGF8, a PAX3–FOXO1 (P3F) transcriptional target, is required for P3F-driven tumorigenicity and, when aberrantly expressed, can maintain tumorigenicity in P3F-independent recurrent tumors. We report in this study that FGF8, FGFR1, and FGFR4 are often highly expressed in FP-RMS tumors. High FGF8 expression in FP-RMS cells is associated with high sensitivity to an FGFR4 inhibitor and a pan-FGFR inhibitor. Although downregulating FGF8 resulted in loss of sensitivity to these inhibitors, FGF8 upregulation in myoblasts decreased FGFR4 expression and sensitized the cells to an FGFR1 inhibitor and a pan-FGFR inhibitor. FGF8 downregulation of FGFR4 expression was reverted by inhibitors of FGFR1, MEK, or ERK, thus defining a signaling pathway by which FGF8 mediates this regulatory effect. Finally, high FGF8 expression in P3F-independent recurrent tumors was attributable to a rearrangement of viral long terminal repeat (LTR) sequences into the FGF8 3′ untranslated region, resulting in increased FGF8 mRNA stability. These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.

3 November 2026
Verified
Other
Open access
SZShabir Zargar
Shabir Zargar
PRPawan Kumar Raut
Pawan Kumar Raut
HKHana Kim
Hana Kim
SBSalah Boudjadi
Salah Boudjadi
RHRachel A. Hoffman
Rachel A. Hoffman
FBFrederic G. Barr
Frederic G. Barr
Table S2. RNA expression of genes in region surrounding upstream P3F binding siteRNA Seq.

17 August 2026 in Molecular Cancer Research
Verified
Journal Article
Open access
SZShabir Zargar
Shabir Zargar
PRPawan Kumar Raut
Pawan Kumar Raut
HKHana Kim
Hana Kim
SBSalah Boudjadi
Salah Boudjadi
RHRachel A. Hoffman
Rachel A. Hoffman
FBFrederic G. Barr
Frederic G. Barr
Alveolar rhabdomyosarcoma (RMS), an aggressive pediatric soft-tissue cancer, is driven by the oncogenic fusion transcription factor PAX3::FOXO1 (P3F) or PAX7::FOXO1. In a subset of fusion-positive RMS (FP-RMS) cases, amplification of the MIR17HG locus leads to overexpression of the miR-17-92 cluster of microRNAs (miRNA). However, miR-17-92 is also highly expressed in FP-RMS tumors lacking this amplification, suggesting alternative regulatory mechanisms. In this study, we show that P3F and MYCN cooperatively drive miR-17-92 expression in FP-RMS. CRISPR/Cas9-mediated knockout of P3F or MYCN in FP-RMS cell lines substantially reduced miR-17-92 expression. Using a human myoblast line or low P3F FP-RMS variant with inducible P3F or MYCN expression, P3F or MYCN alone induces minimal to low miR-17-92 expression, whereas introduction of both MYCN and P3F leads to robust activation of the miR-17-92 cluster and acquisition of oncogenic phenotypes. Chromatin immunoprecipitation sequencing revealed a P3F-binding motif located 1.84 Mb upstream of the MIR17HG promoter. CRISPR-mediated deletion of this region in the myoblast system resulted in marked reduction of miR-17-92 expression and impaired oncogenic transformation. Functional inhibition of mature miRNAs of this cluster in FP-RMS cells using miRNA-sponge constructs suppressed proliferation and transformation. In the myoblast model system, transduction studies with exogenous miR-17-92 or miRNA-sponge expression constructs indicated that miR-17-92 is necessary but not sufficient for oncogenic transformation. Implications: These findings establish a cooperative transcriptional axis in FP-RMS involving P3F and MYCN that activates MIR17HG through a distal regulatory element, thereby contributing to oncogenic behavior and uncovering a novel mechanistic vulnerability.

2 March 2026
Verified
Other
Open access
SBSalah Boudjadi
Salah Boudjadi
HKHana Kim
Hana Kim
BCBishwanath Chatterjee
Bishwanath Chatterjee
PRPawan Kumar Raut
Pawan Kumar Raut
TNThanh Hung Nguyen
Thanh Hung Nguyen
FBFrederic G. Barr
Frederic G. Barr
RNA expression in engineered FP-RMS cells and myoblast lines